Practical info Given the conditional recommendation against using remdesivir for patients with critical COVID-19, practical considerations were felt to be less relevant here. See practical info for use of remdevisir in patients with non-severe or severe COVID-19 if needed.

Practical info for use of remdevisir in patients with non-severe or severe COVID-19: Route, dosage and duration: Additional considerations are available in three summaries of practical issues (remdesivir for COVID-19, administration of remdesivir for COVID-19, safety and monitoring in patients receiving remdesivir for COVID-19). Here follows a brief summary of the key points:

• The recommended dose for remdesivir is one dose daily as intravenous infusion. Remdesivir is given as 200 mg intravenously on Day 1, followed by 100 mg intravenously on Days 2–10. Shorter regimens of 5 days are described in the smaller trials and local practice may be followed.
• Administration should be as early as possible in the time course of the disease.
• One should use caution when administering remdesivir to patients with significant liver or kidney disease.
• The GDG noted that there is insufficient evidence to make a recommendation around use in children and further studies are needed.
• Additionally, the trials did not enrol pregnant or breastfeeding individuals. The decision regarding use of this therapeutic should be made between the pregnant individual and their health care provider while discussing whether the potential benefit justifies the potential risk to the pregnant individual and fetus (see Research evidence and WHO information sheet).